Davita Inc vs First Citizens BancShares Inc — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while First Citizens BancShares Inc trades at $2,068.39 (market cap $22.94B). The key difference: First Citizens BancShares Inc is far larger — about 2× Davita Inc's market cap, and First Citizens BancShares Inc pays a 0.41% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and First Citizens BancShares Inc for 29 Days on average.
| DVA | FCNCA | |
|---|---|---|
Market Cap | $11.29B | $22.94B |
Volume | 582,204 | 91,668 |
Sector | Health | Sector/Thematic |
52-Week High | $240.96 | $2.29K |
52-Week Low | $103.87 | $1.64K |
Typical Hold Time | 114 Days | 29 Days |
Enterprise Value | $24.01B | — |
Dividend Yield | — | 0.41% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
First Citizens BancShares (FCNCA) trades at $2,068.39, down slightly by 0.15% with a bearish technical signal. The company demonstrates strong fundamentals with a P/E of 11.08 and net income margin of 25.23%, having beaten earnings estimates for three consecutive quarters. Recent business developments include branch acquisitions and new financing initiatives, while analyst consensus shows 82% hold ratings with a $2,290 price target.
FCNCA presents a mixed outlook with strong profitability metrics offset by bearish technical indicators. Investment opportunity lies in continued earnings outperformance and strategic expansion, while risks include negative cash flow trends and institutional selling pressure. The stock offers value characteristics but requires monitoring of technical support levels near $2,028.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →